17
Registered trials
6
Recruiting
5
Completed trials
2
Countries active
25
Unique IMPs
100%
Results reported
100%
5 of 5 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).
Top indications
Top IMPs
GALLIUM (68GA), HUMAN ALBUMIN AS MACROAGGREGATES
2
(S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE
1
2-[[5-[3-[[6-[[(5S)-5-CARBOXY-5-[[(1S)-1,3-DICARBOXYPROPYL]CARBAMOYLAMINO]PENTYL]AMINO]-6-OXOHEXYL]AMINO]-3-OXOPROPYL]-2-OXIDOPHENYL]METHYL-[2-[[5-(2-CARBOXYETHYL)-2-OXIDOPHENYL]METHYL-(CARBOXYLATOMETHYL)AMINO]ETHYL]AMINO]ACETATE:GALLIUM-68(3+) HYDRON
1
ACETYLSALICYLIC ACID
1
APIXABAN
1
BARICITINIB
1
BOTULINUM TOXIN TYPE A
1
CAPSAICIN
1
FLUDEOXYGLUCOSE (18F)
1
GALLIUM (68GA) CHLORIDE
1
GOZETOTIDE
1
GRAPHITE
1
All trials
17 totalShowing 1–17 of 17 trials